Erratum
10 October 2022
10 October 2022
Harman K. Rahal, James H. Tabibian, Rachel B. Issaka, Sandra Quezada, Darrell M. Gray, Sophie Balzora, Liu Yang, Jayraan Badiee, Folasade P. May – 10 October 2022
Tung Huynh, Stephanie Ma, Ke‐Qin Hu – 10 October 2022 – Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long‐term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase–to–platelet ratio index (APRI) and Fibrosis‐4 index (FIB‐4) scores remain unknown.
Cristina Ripoll, Luis Ibáñez‐Samaniego, Beatrix Neumann, Javier Vaquero, Robin Greinert, Rafael Bañares, Alexander Zipprich – 10 October 2022 – The aim of this study was to evaluate potential criteria for defining hyperdynamic circulation in patients with cirrhosis according to the severity of ascites and its association with the activation of vasoactive systems and markers of systemic inflammation. Cross‐sectional study of patients with cirrhosis and right heart catheter measurement from two different academic centers.
Scott McHenry, Xiaoyu Zong, Mengyao Shi, Cassandra D.L Fritz, Katrina S. Pedersen, Linda R. Peterson, Jeffrey K. Lee, Ryan C. Fields, Nicholas O. Davidson, Yin Cao – 10 October 2022 – Metabolic syndrome may contribute to the rising incidence of multiple gastrointestinal (GI) cancers in recent birth cohorts. However, other than hepatocellular carcinoma, the association between nonalcoholic fatty liver disease (NAFLD) and risk of non‐liver GI cancers is unexplored.
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Anahita Rabiee, Yanhong Deng, Maria Ciarleglio, Jean L. Chan, Monica Pons, Joan Genesca, Guadalupe Garcia‐Tsao – 9 October 2022 – Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg, identifies patients with compensated cirrhosis at a high risk of decompensation. However, HVPG is an invasive and nuanced method.
Dawei Ding, Guanya Guo, Yansheng Liu, Linhua Zheng, Gui Jia, Juan Deng, Ruiqing Sun, Xiufang Wang, Changcun Guo, Yulong Shang, Ying Han – 9 October 2022 – Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in patients with cirrhosis remain unclear.